Sana’s quest to usher in next generation of cell, gene therapies

Founded by ex-Juno execs, Sana reveals $700M war chest, plans to develop therapies for wide swath of diseases

With $700 million in its coffers, Sana has broad goals to develop cell and gene therapies that address a wide swath of diseases, with its sights set beyond cancer and rare diseases.

While the biotech is mostly mum on its technologies and pipeline, it called out particular historical problems with the modalities that hint at how it plans to push cell and gene therapy to the next frontier. These include delivery to specific cell types and manufacturing challenges.

Sana Biotechnology Inc. said Tuesday that the total amount raised includes cash installments based on two separate valuations.

Read the full 959 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers